Aprocitentan, a dual endothelin receptor antagonist, demonstrated superior and sustained effectiveness in reducing blood pressure in patients with resistant hypertension.
Does aprocitentan reduce blood pressure in patients with resistant hypertension?
Aprocitentan, a newly FDA-approved dual endothelin receptor antagonist, offers a novel and effective therapeutic option for patients with difficult-to-treat resistant hypertension.
ABSTRACT: Hypertension is a major risk factor for cardiovascular disease, and a major contributor to global morbidity and mortality. In particular, resistant hypertension (rHTN), defined as blood pressure that remains elevated despite treatment with at least three antihypertensive agents including a diuretic, continues to be a major pharmacotherapeutic challenge. Traditional antihypertensive drugs often fail in patients with rHTN, underscoring the need for novel therapies. This is a brief mini-review of aprocitentan, a new drug that promises a glimmer of hope for patients with rHTN. This drug is a dual endothelin (ET) receptor antagonist that blocks both ET A and ET B receptors. Given that these two receptors are critical players in vasotone regulation, antagonizing them, such as by aprocitentan, would be expected to significantly reduce blood pressure in patients with rHTN. Indeed, the PRECISION clinical trial demonstrated aprocitentan's superior effectiveness in reducing blood pressure in resistant patients, and the effects were sustained. Aprocitentan has been recently FDA-approved, marking a major milestone in hypertension management, offering hope for patients with difficult-to-treat hypertension.
Ali H. Eid (Tue,) conducted a review in Resistant hypertension. Aprocitentan was evaluated. Aprocitentan, a dual endothelin receptor antagonist, demonstrated superior and sustained effectiveness in reducing blood pressure in patients with resistant hypertension.